Literature DB >> 31324362

c-Myc Overexpression Promotes Oral Cancer Cell Proliferation and Migration by Enhancing Glutaminase and Glutamine Synthetase Activity.

Tao Wang1, Bolei Cai2, Mingchao Ding2, Zhongping Su2, Yanpu Liu3, Liangliang Shen4.   

Abstract

BACKGROUND: This study aimed to investigate whether glutaminase (GLS) and glutamine synthetase (GS) are involved in c-Myc-mediated tumor development in oral cancer.
METHODS: The correlation between the expressions of c-Myc, GLS, and GS in clinical samples and the clinicopathologic features of oral cancer were examined using immunohistochemistry and quantitative real-time polymerase chain reaction. After overexpressing the c-Myc gene and using an inhibitor of GLS or GS, functional experiments were performed to confirm the effects of c-Myc, GLS and GS on proliferation, cell cycle and migration in KB oral cancer cells. The expressions of E-cadherin and N-cadherin were determined by immunofluorescence assays in KB cells overexpressing c-Myc in the presence of GLS or GS inhibitors.
RESULTS: The protein expression of GS was correlated with the Tumor, Lymph Node, and Metastasis (TNM) stage. In addition, c-Myc mRNA levels were positively correlated with GS mRNA levels. Overexpression of c-Myc increased the colonies derived from oral cancer cells and caused more cells to be in S phase compared with the mock-vehicle group. The migratory speed of KB cells was promoted by overexpression of c-Myc compared to the mock-vehicle group. However, these effects were effectively reversed in the presence of GLS or GS inhibitor. Furthermore, c-Myc could inhibit E-cadherin protein expression while promoting N-cadherin expression by enhancing the activity of GLS and GS.
CONCLUSIONS: c-Myc overexpression promotes oral cancer cell proliferation and migration by enhancing GLS and GS activity. Our findings are beneficial for the identification of novel molecular targets for the prevention and treatment of oral cancer.
Copyright © 2019 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glutaminase; Glutamine synthetase; Metabolic reprogramming; Oral cancer; c-Myc

Year:  2019        PMID: 31324362     DOI: 10.1016/j.amjms.2019.05.014

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  5 in total

1.  Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.

Authors:  Henrique J Cardoso; Marília I Figueira; Cátia V Vaz; Tiago M A Carvalho; Luís A Brás; Patrícia A Madureira; Paulo J Oliveira; Vilma A Sardão; Sílvia Socorro
Journal:  Cell Oncol (Dordr)       Date:  2021-01-19       Impact factor: 6.730

2.  GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.

Authors:  Valentino Clemente; Asumi Hoshino; Mihir Shetty; Andrew Nelson; Britt K Erickson; Ruth Baker; Nathan Rubin; Mahmoud Khalifa; S John Weroha; Emil Lou; Martina Bazzaro
Journal:  Cancer Res Commun       Date:  2022-08-10

3.  Taohong Siwu Decoction exerts anticancer effects on breast cancer via regulating MYC, BIRC5, EGF and PIK3R1 revealed by HTS2 technology.

Authors:  Yu Gui; Yifei Dai; Yumei Wang; Shengrong Li; Lei Xiang; Yuqin Tang; Xue Tan; Tianli Pei; Xilinqiqige Bao; Dong Wang
Journal:  Comput Struct Biotechnol J       Date:  2022-06-26       Impact factor: 6.155

Review 4.  Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc.

Authors:  Daniel Massó-Vallés; Laura Soucek
Journal:  Cells       Date:  2020-04-04       Impact factor: 6.600

Review 5.  Identification of Metabolism-Associated Biomarkers for Early and Precise Diagnosis of Oral Squamous Cell Carcinoma.

Authors:  Yuhan Wang; Xiaoxin Zhang; Shuai Wang; Zihui Li; Xinyang Hu; Xihu Yang; Yuxian Song; Yue Jing; Qingang Hu; Yanhong Ni
Journal:  Biomolecules       Date:  2022-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.